TerrAscendTSNDF +2.79%32 Days Payable is 117.67 as of Mar. 2026, which is 4% below its 10-year median of 122.07. GuruFocus rates TSNDF with a GF Score™ of 32/100 and a GF Value™ of $0.99 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 923 Drug Manufacturers companies, TerrAscend ranks better than 63.92% on this metric.
TerrAscend's average Accounts Payable for the
three
months ended in Mar. 2026 was $39.9 Mil. TerrAscend's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $30.9 Mil.
Hence, TerrAscend's Days Payable for the
three
months ended in Mar. 2026 was 117.67.
The historical rank and industry rank for TerrAscend's Days Payable or its related term are showing as below:
TSNDF'
s Days Payable Range Over the Past 10 Years
Min: 88.05 Med: 122.07 Max: 413.33
Current: 115.66
During the past 10 years, TerrAscend's highest Days Payable was 413.33. The lowest was 88.05. And the median was 122.07.
TSNDF's Days Payable is ranked better than 63.92% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs TSNDF: 115.66
TerrAscend's Days Payable
declined
from Mar. 2025 (130.24) to Mar. 2026 (117.67).
It may suggest that TerrAscendaccelerated paying its suppliers.
TerrAscend Days Payable Related Terms
TerrAscend Days Payable Historical Data
* Premium members only.
The historical data trend for TerrAscend's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TerrAscend's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TerrAscend Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TerrAscend's Days Payable distribution charts can be found below:
* The bar in red indicates where TerrAscend's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
TerrAscend's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TerrAscend (TSNDF) has a Days Payable of 117.67 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on TerrAscend and its competitors. This is near median its historical median of 122.07. Over the past decade, TerrAscend's Days Payable has ranged from 88.05 to 413.33. According to the industry distribution chart, TerrAscend ranks #333 out of 923 companies in the Drug Manufacturers industry, placing it in the top 36.1%.
Is TerrAscend's Days Payable too high?
TerrAscend's current Days Payable of 117.67 is near median its 10-year median of 122.07. Over the past 10 years, this metric has ranged from a low of 88.05 to a high of 413.33. The Drug Manufacturers industry median Days Payable is 90.98. TerrAscend's value of 117.67 is 29.3% above this industry median. Based on the distribution chart, TerrAscend ranks #333 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, TerrAscend has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TerrAscend's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TerrAscend ranks #333 out of 923 companies for Days Payable. This puts TerrAscend in the upper half of its industry. The industry median Days Payable is 90.98. TerrAscend's value of 117.67 is 29.3% above this benchmark. Historically, TerrAscend's own Days Payable has ranged from 88.05 to 413.33 over the past decade. While the company's 10-year median is 122.07 vs. the industry median of 90.98, TerrAscend has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TerrAscend's current Days Payable of 117.67 is 29.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on TerrAscend and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TerrAscend's current Days Payable is 117.67, which is near median its own 10-year median of 122.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TerrAscend stock overvalued right now?
Based on GuruFocus' analysis, TerrAscend (TSNDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.99, compared to a current price of $0.65 — trading 34.8% below its estimated fair value. The current Days Payable is 117.67, which is near median its 10-year median of 122.07 and 29.3% above the Drug Manufacturers industry median of 90.98. TerrAscend's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For TerrAscend (TSNDF), the current Days Payable is 117.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TerrAscend (TSNDF) Overvalued in 2026?
Based on GuruFocus' analysis, TerrAscend stock appears to be undervalued.
The current stock price of $0.65 is trading 34.8% below its estimated GF Value™ of $0.99.
GuruFocus considers TerrAscend to be Possible Value Trap.
Key valuation signals for TSNDF:
Days Payable: 117.67 (near median its 10-year median of 122.07)
GF Value™: $0.99 vs. price of $0.65 (34.8% below fair value)
Industry Position: 29.3% above the Drug Manufacturers median (#333 of 923)
No single metric tells the full story. See the TSNDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TerrAscend Corp is a company focused on creating and delivering cannabis products and services that meet the evolving needs of its patients. It also provides education and support programs to physicians and patients through healthcare professionals. In addition, the firm operates in California, Maryland, New Jersey, and Pennsylvania, with retail operations in Ohio and Canada. It operates The Apothecarium and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. The firm has one operating segment, being the cultivation, production, and sale of cannabis products, with subsidiaries located in Canada and the United States. The company generates key revenue from the United States.
32GF Score
Get the complete analysis for TSNDF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSNDF has been successfully added to your 
